PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 5, 2025Diabetes Therapy0 citationsOpen Access

Comparing Cardiovascular Protection of Dual and Selective Incretin Receptor Agonists in Diabetes

Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT

View Full Paper
Ask AI
Bookmark
Share

Authors

GFGian Paolo Fadini

Discussion

Loading...

Member takes

Overview

SURPASS-CVOT trial compares cardiovascular outcomes of dual incretin receptor agonists with selective GLP-1 receptor agonists, highlighting significant findings.

Key Points

  • The SURPASS-CVOT trial demonstrated noninferiority between dual incretin receptor agonists and selective GLP-1 receptor agonists for major adverse cardiovascular events.
  • Tirzepatide showed a 28% reduction in MACE risk compared to imputed placebo, yet did not exceed dulaglutide's efficacy.
  • Despite greater reductions in HbA1c and weight loss, tirzepatide provided limited incremental cardiovascular benefits in type 2 diabetes patients.
  • The trial's design questions current cardiovascular treatment paradigms, indicating a potential therapeutic ceiling for diabetes care.

Cite This Study

Gian Paolo Fadini (2025) studied this question.

synapsesocial.com/papers/68bb46a86d6d5674bccfe311https://doi.org/10.1007/s13300-025-01784-x
View Full Paper
Ask AI
Bookmark
Share